BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, including the Company’s proprietary WaterLase®, and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography, intra oral scanners, and chair-side milling machines and 3-D printers for dentistry, issued a statement in response to a press release issued by Oracle Partners L.P. (“Oracle”) announcing its nomination of four director candidates to stand for election to the BIOLASE® Board of Directors at the Company’s 2014 Annual Meeting of Stockholders. BIOLASE shareholders are not required to take any action at this time. BIOLASE Inc (NASDAQ:BIOL) shares after opening at $-5.71 on last trade day and at the end of the day closed at $2.64. Company price to sales ratio in past twelve months was calculated as 1.42 and price to cash ratio as20.45. BIOLASE Inc (NASDAQ:BIOL) showed a negative weekly performance of -8.33%.
Durata Therapeutics (NASDAQ:DRTX) had its target price lifted by Jefferies Group from $10.00 to $12.40 in a research note released on Monday morning, StockRatingsNetwork.com reports. Durata Therapeutics Inc (NASDAQ:DRTX) shares fell -6.97% in last trading session and ended the day on $15.49. DRTX return on equity ratio is recorded as -133.70% and its return on assets is -60.40%. Durata Therapeutics Inc (NASDAQ:DRTX) yearly performance is 82.67%.
NovaBay Pharmaceuticals Inc:Priced an underwritten public offering of an aggregate of 5,600,000 shares of its common stock, and 18-month warrants to purchase up to an aggregate of 1,400,000 shares of common stock.At a combined price to the public of $1.20 for aggregate gross proceeds of $6,720,000.The offering is expected to close on or about March 25. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) shares moved down -5.56% in last trading session and was closed at $1.19, while trading in range of $1.11 – $1.21. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) year to date (YTD) performance is -3.25%.
Equities researchers at William Blair assumed coverage on shares of Inogen (NASDAQ:INGN) in a research report issued on Wednesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock. Inogen Inc (NASDAQ:INGN) weekly performance is -7.50%. On last trading day company shares ended up $1.850. Inogen Inc (NASDAQ:INGN) distance from 50-day simple moving average (SMA50) is 2.43%. Analysts mean target price for the company is $26.00.